Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 11/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450587 | 1.00 | HPRT1 (0.55) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL15516660 | 1.00 | HPRT1 (0.55) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL97303 | 0.91 | HPRT1 (0.51) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL14669210 | 0.90 | CYP3A4 (0.53) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL14669198 | 0.90 | CYP3A4 (0.53) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL14669190 | 0.90 | CYP3A4 (0.53) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL3860363 | 0.90 | HPRT1 (0.56) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL29624179 | 0.90 | HPRT1 (0.56) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL9193126 | 0.90 | HPRT1 (0.56) | HPRT1CYP3A4FGFR1SLC22A6CDK1 | |
| SCHEMBL8911145 | 0.89 | FGFR1 (0.54) | HPRT1CYP3A4FGFR1SLC22A6TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157793-A1 | Modified nucleosides as antiviral agents | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2004-08-12 | — | — | US | claimed |
| WO-2004043402-A2 | MODIFIED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| EP-2604620-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3521297-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3521297-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3159351-A2 | MODIFIED 3'-AZIDO-4'-ETHYNYL-NUCLEOSIDES AS ANTIVIRAL AGENTS | Gilead Pharmasset LLC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-1937825-B1 | MODIFIED 4'-NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD PHARMASSET LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9382286-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2604620-B1 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
| US-5861500-A | ISOLATED DNA MOLECULES WHICH ENCODES INTERLEUKINS AND ANTISENSE OLIGONUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-01-19 | — | — | US | disclosed |
| US-5859225-A | NUCLEIC ACIDS AND POLYPEPTIDES FOR DIAGNOSIS AND THERAPY; HYBRIDIZATION PROBES; ANTISENSE MOLECULES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-01-12 | — | — | US | disclosed |
| US-5853734-A | Glycoprotein L and clycoprotein M from kaposi's sarcoma associated herpesvirus, DNA encoding same and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-12-29 | — | — | US | disclosed |
| US-5854398-A | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-12-29 | — | — | US | disclosed |
| US-5854418-A | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-12-29 | — | — | US | disclosed |
| US-5849564-A | Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-12-15 | — | — | US | disclosed |
| US-5831064-A | Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-11-03 | — | — | US | disclosed |
| US-5830759-A | ISOLATED NUCLEIC ACIDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-11-03 | — | — | US | disclosed |
| US-5801042-A | DNA AND NUCLEIC ACIDS FOR HERPESVIRUS GLYCOPROTEIN H, PLASMIDS AND GENOMES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | HPRT1 83/4885CYP3A4 556/4885FGFR1 711/4885 |
| US-20040157793-A1 | Modified nucleosides as antiviral agents | PNP, SAMHD1, SLC29A1 | HPRT1 17/4885CYP3A4 229/4885FGFR1 4286/4885 |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | FEN1, RCE1, APEX1 | HPRT1 1690/4885CYP3A4 2905/4885FGFR1 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.